🇺🇸 FDA

Company profile · Sponsor

ArriVent

ArriVent BioPharma

AVBP · NYSE biotech NEWTOWN SQUARE, PA, USA
Pipeline
7
Drugs
0
Patents
0

Quick answer

ArriVent (AVBP) is a biotech company. headquartered in NEWTOWN SQUARE, PA, USA. listed on NYSE. NovaPharmaNews links 7 pipeline programs, 0 drugs, and 0 patents to this profile..

Company facts

Ticker AVBP
Exchange NYSE
Company type biotech
Headquarters NEWTOWN SQUARE, PA, USA
SEC CIK 0001868279

Pipeline (7)

Search pipeline →

  1. Firmonertinib

    ArriVent

    NSCLC

    phase 3 small molecule active

    1 trial

  2. Firmonertinib

    ArriVent

    Non-Small-Cell Lung Cancer

    phase 3 small molecule active

    1 trial

  3. Furmonertinib, AFATINIB, OSIMERTINIB, OSIMERTINIB, AFATINIB, AFATINIB

    ArriVent

    Advanced or Metastatic Non-Small-Cell Lung Cancer With Epidermal Growth Factor Receptor P-Loop and Alpha C-Helix Compressing (PACC) Uncommon Mutations

    phase 3 small molecule active

    1 trial

  4. furmonertinib 240 mg oral, daily

    ArriVent

    Metastatic Non-Small Cell Lung Cancer

    phase 3 small molecule active

    1 trial

  5. A Study to Evaluate the Safety, Pharmacokinetics, and Antitumor Activity of Furmonertinib in Patients with Non-Small Cell Lung Cancer with Activating EGFR or HER2 Mutations (FURTHER)

    ArriVent

    Non-Small Cell Lung Cancer (NSCLC) harboring activating EGFR or HER2 kinase domain mutations

    phase 1 other active

    1 trial

  6. Furmonertinib

    ArriVent

    Non-Small Cell Lung Cancer (NSCLC)

    phase 1 small molecule active

    1 trial

  7. MRG007

    ArriVent

    Locally Advanced or Metastatic Solid Tumors

    phase 1 small molecule active

    1 trial

Frequently asked questions

What is ArriVent?

ArriVent (AVBP) is a biotech company. headquartered in NEWTOWN SQUARE, PA, USA. listed on NYSE. NovaPharmaNews links 7 pipeline programs, 0 drugs, and 0 patents to this profile..

What pipeline programs does ArriVent sponsor?

We track 7 ClinicalTrials.gov-linked programs for ArriVent, including Firmonertinib and 6 more. Open each program for phase, modality, NCT IDs, and indication details.

Where does ArriVent company data come from?

Profiles combine SEC EDGAR (CIK/ticker), ClinicalTrials.gov sponsor links, FDA drug records, and USPTO patent metadata. See our data sources page. This profile is for professional reference, not investment advice.